News | February 16, 2012

FDA Approves Velomedix Study of Rapid Therapeutic Hypothermia AMI Management

February 16, 2012 — Velomedix Inc., a clinical stage medical device company, received investigational device exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to evaluate the use of rapid therapeutic hypothermia for the treatment of patients suffering an acute myocardial infarction (AMI or heart attack). The conditional approval allows the company to initiate a clinical trial at select sites in the United States.

Therapeutic hypothermia has been shown to significantly improve outcomes for several acute events such as cardiac arrest, heart attack, and acute ischemic stroke. It has also been used with great success for spinal cord injury. While there are several technologies currently being marketed for hypothermia management, Velomedix’s proprietary technology delivers unparalleled cooling speed and procedural efficiency that is expected to result in enhanced clinical outcomes and enable more widespread clinical adoption of the therapy. “While current technologies can reach a therapeutic target temperature of 33 C in one to two hours, the Velomedix system has shown the ability to achieve 33 C in less than 15 minutes,” commented Jeff Gold, president and CEO of Velomedix.

“For AMI patients requiring an intervention to open a blocked artery, the ability to deliver rapid cooling is crucial to optimizing the protective benefits of therapeutic hypothermia while still complying with mandated hospital ‘time-to-treatment’ standards,” added Griff Tully, M.D., Velomedix’s vice-president and chief medical officer.

The recently approved IDE study will build upon limited, yet significant, data developed over the last eight years for the use of therapeutic hypothermia for heart attack victims. Though the early randomized studies clearly pointed to the potential benefits of therapeutic hypothermia in this patient population, the effectiveness of the therapy was limited by the slow cooling times of the technologies employed and, as such, failed to meet the primary clinical endpoints. More recent studies have shown that rapid cooling, as enabled by Velomedix’s proprietary system, can result in clinical results that rival the best data extracted from earlier studies. Study patients who were rapidly and effectively treated with therapeutic hypothermia showed up to a 50 percent reduction in the amount of heart muscle lost during a major heart attack. This reduction is expected to correlate with improved survival rates and enhanced quality of life post-infarct.

It is anticipated the Velomedix IDE study will begin enrolling patients in the second half of 2012.

For more information: www.velomedix.com

Related Content

Pregnancy-Related Heart Failure Strikes Black Women Twice as Often as Other Races
News | Womens Healthcare| October 19, 2017
African American women were found to be twice as likely to be diagnosed with peripartum cardiomyopathy as compared to...
MRI May Predict Neurological Outcomes for Cardiac Arrest Survivors
News | Sudden Cardiac Arrest| October 18, 2017
Magnetic resonance imaging (MRI)-based measurements of the functional connections in the brain can help predict long-...
Xarelto Significantly Reduces Major Cardioavascular Events in Stable CAD and PAD Patients
News | Pharmaceuticals| October 18, 2017
October 18, 2017 — Results from the pivotal Phase 3 COMPASS study found that the...
Baylis Medical and Siemens Co-Sponsor Transseptal Access Training Course
News | EP Lab| October 18, 2017
Baylis Medical Co. Inc. and Siemens Healthineers are co-sponsoring a first-of-its kind training program aimed at...
Societies Issue New Performance and Quality Measures for Treating Patients with Heart Attack
News | Cath Lab| October 17, 2017
The American College of Cardiology and the American Heart Association recently released updated clinical performance...
First Patient Enrolled in U.S. Arm of ALIVE Pivotal Heart Failure Trial
News | Heart Failure| October 17, 2017
October 17, 2017 — BioVentrix Inc. recently announced enrollment of the first patient in the U.S.
Dee Dee Wang runs Henry Ford Hospital's 3D printing lab for its complex structural heart cardiology program.

Dee Dee Wang, M.D., runs Henry Ford Hospital's 3-D printing lab that supports its complex structural heart program.

Feature | 3-D Printing| October 13, 2017 | Dave Fornell
Three-dimensional (3-D) printed anatomic models created from a patient’s computed tomography (CT), magnetic resonance...
Low Mortality and Stroke Risks Displayed for Minimally Invasive Aortic Valve Replacements
News | Heart Valve Technology| October 11, 2017
An analysis of more than 1,000 minimally invasive aortic valve replacements and more than 400 additional associated...
New Evaluation Sends Low-Risk ER Chest Pain Patients Home Sooner
News | Cardiac Diagnostics| October 10, 2017
A new evaluation to determine whether emergency room patients with chest pain can go home and follow up with their...
Videos | Chronic Total Occlusion (CTO)| October 09, 2017
Bill Lombardi, M.D., director of complex coronary artery interventions at the University of Washington, discusses the
Overlay Init